Evidence map›Paper›PMID 40208106›Full record

ArticleThe Journal of clinical endocrinology and metabolism2025

Prediabetes and Risk of All-Cause and Cause-Specific Mortality: A Prospective Study of 114 062 Adults in Mexico City.

Carlos Alberto Fermín-Martínez, Omar Yaxmehen Bello-Chavolla, César Daniel Paz-Cabrera, Daniel Ramírez-García, Jerónimo Perezalonso-Espinosa, Luisa Fernández-Chirino, Arsenio Vargas-Vázquez, Juan Pablo Díaz-Sánchez, Padme Nailea Méndez-Labra, Alejandra Núñez-Luna and 12 more

Abstract read
In one paragraph

Article in The Journal of clinical endocrinology and metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

22 authors.

Carlos Alberto Fermín-MartínezResearch Division, Instituto Nacional de Geriatría, Mexico City 10200, Mexico.
Omar Yaxmehen Bello-ChavollaResearch Division, Instituto Nacional de Geriatría, Mexico City 10200, Mexico.ORCID 0000-0003-3093-937X
César Daniel Paz-CabreraResearch Division, Instituto Nacional de Geriatría, Mexico City 10200, Mexico.
Daniel Ramírez-GarcíaResearch Division, Instituto Nacional de Geriatría, Mexico City 10200, Mexico.
Jerónimo Perezalonso-EspinosaResearch Division, Instituto Nacional de Geriatría, Mexico City 10200, Mexico.
Luisa Fernández-ChirinoResearch Division, Instituto Nacional de Geriatría, Mexico City 10200, Mexico.ORCID 0000-0002-8326-1219
Arsenio Vargas-VázquezMD/PhD (PECEM) Program, Facultad de Medicina, Universidad Nacional Autónoma de México, Mexico City 04360, Mexico.ORCID 0000-0002-0051-7689
Juan Pablo Díaz-SánchezResearch Division, Instituto Nacional de Geriatría, Mexico City 10200, Mexico.
Padme Nailea Méndez-LabraResearch Division, Instituto Nacional de Geriatría, Mexico City 10200, Mexico.
Alejandra Núñez-LunaResearch Division, Instituto Nacional de Geriatría, Mexico City 10200, Mexico.
Martín Roberto Basile-AlvarezResearch Division, Instituto Nacional de Geriatría, Mexico City 10200, Mexico.
Paulina Sánchez-CastroResearch Division, Instituto Nacional de Geriatría, Mexico City 10200, Mexico.
Fiona BraggClinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford OX3 7LF, UK.ORCID 0000-0002-9181-6886
Louisa Gnatiuc FriedrichsClinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford OX3 7LF, UK.
Diego Aguilar-RamírezClinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford OX3 7LF, UK.
Jonathan R EmbersonClinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford OX3 7LF, UK.
Jaime BerumenFacultad de Medicina, Universidad Nacional Autónoma de México, Mexico City 04360, Mexico.
Pablo Kuri-MoralesInstituto Tecnológico y de Estudios Superiores de Monterrey, Monterrey 64700, Mexico.ORCID 0000-0002-0704-9507
Roberto Tapia-ConyerFacultad de Medicina, Universidad Nacional Autónoma de México, Mexico City 04360, Mexico.
Jesus Alegre-DíazExperimental Research Unit, Faculty of Medicine, National Autonomous University of Mexico, Mexico City 06720, Mexico.
Jacqueline A SeiglieDiabetes Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
Neftali Eduardo Antonio-VillaDepartment of Endocrinology, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City 14080, Mexico.ORCID 0000-0002-6879-1078

Funding

REACH-Es: Adapting a digital health tool to improve diabetes medication adherence among Latino adultsK23DK135798 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI Jacqueline Anne Seiglie · 2023 to 2026
$784k
British Heart FoundationCancer Research UKInstituto Nacional de GeriatríaMexican Health MinistryNational Council of Science and TechnologyNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIDDK NIH HHS K23 DK135798UK Medical Research Council K23DK135798UK Medical Research Council MC_UU_00017/2Wellcome TrustWellcome Trust 058299/Z/99
6 · The paper itself

Abstract

backgroundPrediabetes has been associated with increased all-cause and cardiovascular mortality. However, no large-scale studies have been conducted in Mexico or Latin America examining these associations.

methodsWe analyzed data from 114 062 adults without diabetes (diagnosed or undiagnosed) from the Mexico City Prospective Study. Participants were followed until January 1, 2021, for cause-specific mortality. We defined prediabetes according to the American Diabetes Association (ADA; HbA1c ≥ 5.7% to <6.5%) and the International Expert Committee (IEC; HbA1c ≥ 6.0 to <6.5%) definitions. Cox regression adjusted for confounders was used to estimate all-cause and cause-specific mortality rate ratios (RR) for deaths occurring at ages 35 to 74 years associated with prediabetes.

resultsAfter median 18.4 (IQR 17.6-19.7) years of follow-up, individuals with prediabetes had higher risk of all-cause mortality at ages 35 to 74 compared to those without prediabetes (RR 1.13 [1.07-1.20] for ADA-defined and 1.27 [1.17-1.38] for IEC-defined prediabetes), as well as higher risk of cardiovascular (RR 1.23 [1.11-1.37] and 1.44 [1.24-1.67], respectively), renal (RR 1.33 [1.06-1.66] and 1.62 [1.18-2.23], respectively), and acute diabetic deaths (RR 2.62 [1.75-3.93] and 3.42 [2.09-5.61], respectively). The absolute excess risk associated with ADA-defined prediabetes at ages 35 to 74 accounted for 7% of cardiovascular, 9% of renal, and 31% of acute diabetic deaths. IEC-defined prediabetes accounted for 4%, 5% and 14% of cardiovascular, renal, and acute diabetic deaths. Prediabetes-associated excess mortality risks were, at least in part, explained by adiposity.

conclusionPrediabetes is a significant risk factor for all-cause, cardiovascular, renal, and acute diabetic deaths in Mexican adults. Early identification and timely management of prediabetes among individuals at risk of this condition could reduce premature mortality in this population.

Indexed as

Cardiovascular DiseasesPrediabetic StateAdultAgedCause of DeathFemaleFollow-Up StudiesGlycated HemoglobinHumansMaleMexicoMiddle AgedProspective StudiesRisk FactorsGlycated HemoglobinMexican populationmortalityobservational studyprediabetes

Identifiers

PMID40208106
PMCPMC12623046

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.